Applied Therapeutics

Corporate Presentation

November 2022



Disclaimer

This presentation is made by Applied Therapeutics, Inc. (the "Company"). Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be allinclusive or to contain all of the information you may desire. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Various statements in this presentation concerning the Company's future expectations, plans and prospects, including without limitation, the Company's current expectations regarding its strategy, its product candidate selection and development timing, its management team capabilities, and the ability of the Company's product candidates to have a clinically meaningful effect on the target patient populations, constitute forward-looking statements. The use of words such as "may," "might," "will," "should," "expect," "plan," "articipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company's control. Such risks include, but are not limited to: the impact of general economic conditions, general conditions in the biopharmaceutical industries, changes in the global and regional regulatory environments in the jurisdictions in which the Company does or plans to do business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company's current analyses; the expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration and European Medicines Agency; the possibility of having to conduct additional clinical trials and our reliance on third parties such as our licensors and collaboration partners regarding our suite of technologies and product candidates. Further, even if reg

These risks and uncertainties are described more fully under the caption "Risk Factors" in the Company's filings with the Securities and Exchange Commission. Other risks and uncertainties of which the Company is not currently aware may also affect Company's forward-looking statements. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

Applying Science to Transform Lives

Our mission is to create transformative, life-changing treatments for patients who desperately need them

SCIENCE



Targeting pathways with known roles in pathogenesis

Novel compounds with improved potency/selectivity

DEVELOPMENT



Clinical efficacy confirmed via biomarkers

Pursuing expedited regulatory pathways


MARKET




Fatal or debilitating diseases with no approved therapies

Limited / no competition

Innovative Pipeline with Near-Term Milestones



Aldose Reductase Inhibitor Overview



Aldose Reductase is an enzyme implicated in multiple metabolic diseases

AT-007: Blockbuster Opportunity with Late-Stage Programs in 2 Rare Diseases with High Unmet Need and No Approved Treatments

Galactosemia

- Positive adult and pediatric biomarker data
- Orphan Drug Designation
- Pediatric Rare Disease Designation
- Fast-Track Designation
- Phase 3 pediatric outcomes study ongoing; powered for statistical significance at 18 months

SORD Deficiency

- · Preclinical proof of concept
- Positive pilot study results in SORD patients
- Phase 3 study ongoing
- Biomarker data expected Q1 2023; potential for accelerated approval

~7,000 patients in US + EU in each indication (14,000 total)

Near-term revenue opportunity with Composition of Matter patent exclusivity through 2037

- Validated mechanism of action
- US payer feedback supports pricing/coverage

- Strong patient, caregiver, HCP interest
- Convenient, once-daily oral dosing
- · Favorable safety and tolerability profile
- Small commercial footprint needed
- Commercialization prep underway
- Low cost of goods; oral suspension

AT-001: Potential First Therapy in Diabetic Cardiomyopathy, a Highly Prevalent Disease with Blockbuster Potential

Diabetic Cardiomyopathy

- Heart Failure affecting ~20% of diabetics
- Positive proof of concept in Phase 1/2
- ARISE-HF global Phase 3 trial ongoing; data expected YE 2023
- No drugs approved; potential first diseasemodifying treatment in DbCM

Diabetic Peripheral Neuropathy

- Proof of concept with "old" ARIs
- Sub-study embedded in ARISE-HF DbCM Phase 3 (patients with both DbCM and DPN)
- Although pain drugs are approved for symptomatic treatment, no disease-modifying treatments exist;
 Potential first disease-modifying treatment in DPN

DbCM potential market ~6M patients US; 5M EU5

DPN potential market ~9M patients US; 7M EU5

- Validated mechanism of action
- Demonstrated proof of concept
- Patent exclusivity through 2031

- Convenient, twice-daily oral dosing
- Favorable safety and tolerability profile
- Strong KOL support

- Low cost of goods; oral capsules
- Payer feedback supports pricing on par with Entresto / SGLTs

AT-007 GALACTOSEMIA

- Orphan Drug Designation
- Pediatric Rare Disease Designation (PRV)
- Fast-Track Designation

Positive adult & pediatric biomarker data Pediatric Ph 3 clinical outcomes study ongoing



Galactosemia is a Rare Metabolic Disease With No Approved Therapies and Significant Unmet Need

Disease Overview

- Rare autosomal recessive metabolic disease caused by deficiencies in the GALT or GALK enzymes
- Patients are unable to metabolize the simple sugar galactose, which is found in foods but also synthesized endogenously by the body
- Results in long-term CNS complications including speech, cognition, behavior and motor skills deficiencies; ovarian insufficiency in females
- Progressively worsens with age

Mechanism of Disease

- People with Galactosemia are unable to metabolize galactose, which accumulates in cells and tissues
- At abnormally high levels, galactose becomes a substrate for Aldose Reductase, which converts galactose to a toxic and aberrant metabolite, galactitol
- Galactitol is highly toxic (especially to neurons) and causes redox derangement, cell death
- Plasma galactitol level correlates with severity of disease


Standard of Care/ Diagnosis

- No approved therapies to treat Galactosemia
- Mandatory newborn screening in US and most EU countries
- Galactose-restricted diet implemented immediately after birth and adhered to for life
- Dietary restriction prevents newborn fatalities but does not prevent long-term CNS complications due to endogenous galactose production by the body
- Patients are primarily seen by metabolic geneticists


Market Size / Opportunity

- \$1.25B+ WW peak sales potential (US, EU28, JP)
- Known prevalent and addressable population (~3K US, ~7K WW)
- Small commercial footprint focused on KOLs at Centers
 of Excellence
- Strong patient community engagement
- Payer feedback supports access/pricing
- Composition of matter IP through 2037 (not including extensions)

AT-007 Has Demonstrated Effectiveness In Vitro, In Vivo, and in Phase 1/2 Clinical Trials; Registrational Study Readout 2023



Deficiency in GALT or GALK Leads to Inability to Metabolize Galactose; AR Converts Excess Galactose to Toxic Galactitol



CNS Complications:


- Speech Deficiencies
- Cognition/ Learning/ IQ/ Memory
- Behavior/ Psychiatric
- Motor Skills (Tremor, Ataxia)
- Seizures
- Other Complications:
 - Ovarian Insufficiency
 - Cataracts

APPLIED

THERAPEUTICS

Natural History: Galactosemia is a Progressive Disease that Worsens with Age; Disease Severity Correlates with Plasma Galactitol Level


Natural history of disease demonstrates progressive worsening with age




APPLIED THERAPEUTICS

In a Rat Model of Galactosemia, AT-007 Significantly Reduced Toxic Galactitol Levels in All Target Tissues and Normalized the CNS Phenotype


AT-007 treatment decreased galactitol levels in liver, brain and plasma; no compensatory increase in galactose or Gal-1p



AT-007 treatment normalized CNS outcomes on Morris water maze



AT-007 Significantly Reduced Galactitol Levels in the Galactosemia Adult Phase 1/2 Study (ACTION-Galactosemia); Safe and Well-Tolerated





Galactitol Reduction vs. Baseline (Individual Patient Values)




Safety

• Favorable safety and tolerability in core study and 3-month extension

Pharmacokinetics/ Pharmacodynamics


- 20mg/kg dose selected as optimal dose
- PK supports once-daily dosing
- · Rapid, sustained and significant reduction in plasma galactitol
- Galactitol reduction in the brain demonstrated by MR Spectroscopy
- No compensatory increase in galactose or Gal-1p



Maximum Galactitol Reduction vs. Baseline

APPLIED
 THERAPEUTICS


AT-007 Significantly Reduced Galactitol Levels in the ACTION-Galactosemia Kids Pediatric Registrational Clinical Study




All groups	15-30mg/kg	40.19% (p<0.001)
<20kg	30mg/kg	39.83%
20-40kg	0-40kg 20mg/kg 41.43%	
>40kg	15mg/kg	38.29%

Safe and well tolerated

No compensatory increase in galactose or Gal-1p



Award Winning DSA Campaign Performance Reflects Underlying Strong Demand for Galactosemia Education and Treatment



AT-007 SORD DEFICIENCY

Orphan Drug Designation

Preclinical proof of concept demonstrated Positive pilot study completed Registrational Phase 3 study ongoing



SORD Deficiency is a Rare Neurological Disease with No Approved Therapies and High Unmet Need

Disease Overview

- Sorbitol Dehydrogenase Deficiency (SORD Deficiency) is a progressive, debilitating hereditary neuropathy that affects peripheral nerves and motor neurons, resulting in significant disability, loss of sensory function and decreased mobility
- Autosomal recessive genetic disease, caused by mutations in the SORD gene resulting in loss of SORD enzyme function
- Average age of onset is 17 years old

Mechanism of Disease

- Patients with SORD Deficiency are unable to metabolize sorbitol
- Aldose Reductase converts glucose to sorbitol, which then accumulates at up to 100X normal levels in patients with SORD Deficiency
- Sorbitol is toxic to cells (especially neurons), resulting in osmotic stress, redox derangement and energetic destabilization


Standard of Care/ Diagnosis

- No approved therapies to treat SORD Deficiency
- Genetic testing commercially available (GeneDx)
- Prior to 2020, patients were diagnosed symptomatically as CMT2 or dHMN; new screening efforts are quickly recategorizing CMT2/dHMN patients with SORD
- Primarily treated by neurologists/ neuromuscular specialists at Inherited Neuropathy Consortium (INC) Centers of Excellence


Market Size/ Opportunity

- \$1.9B+ WW peak sales potential, \$1.2B+ in US
- ~3,300 individuals in the US with SORD Deficiency;
 7,000 US+EU combined
- Small commercial footprint focused on KOLs at COEs
- Strong patient community engagement
- Payer feedback supports access/pricing
- Composition of matter IP through 2037; IP covering ARI treatment of SORD Deficiency through 2040

AT-007 Has Demonstrated Effectiveness In Vitro, In Vivo, and in a SORD Pilot Study; Phase 3 Biomarker Data Expected in 2022; Outcomes 2023




Aldose Reductase Inhibition Addresses the Underlying Cause of SORD Neuropathy by Preventing Conversion of Glucose to Sorbitol



- People with SORD Deficiency are missing the SORD enzyme, which follows Aldose Reductase in the polyol pathway
 - As a result, people with SORD Deficiency are unable to metabolize sorbitol
 - Sorbitol accumulates in blood, cells and tissues at very high levels
 - High toxic sorbitol levels result in cell death and tissue degeneration, leading to neuropathy

AT-007 Treatment Reduces Sorbitol Levels in SORD Patient Cells; Prevents CNS Phenotype in a Drosophila SORD Deficiency Model

Sorbitol Reduction in Patient Fibroblasts with AT-007 Treatment




- Sorbitol accumulation causes mitochondrial dysfunction and reactive oxygen species formation, resulting in axonal neuropathy
- Treatment with AT-007 reduces sorbitol and prevents downstream neuronal damage
- AT-007 treatment normalizes lower limb function in drosophila


AT-007 Prevents the SORD Disease Phenotype in Drosophila

VW

Sord



SORD mutant flies treated with vehicle (DMSO) or 20ug/ml AT-007 in food for 40 days after eclosion (DAE) AT-007 treatment prevented neuronal degeneration, as visualized by the presence vacuolar structures



Fly geotactic activity was recorded using an automated monitoring system. *yw* files (control) treated with DMSO and SORD deficient files treated with DMSO or 10 µg/ml AT- 007 at 10 DAE. Data are presented as mean ± SE, ***p* < 0.01 from trial-by-trial comparisons.


APPLIED THERAPEUTICS Oral presentation Peripheral Nerve Society Annual meeting 2021: Pre-Clinical Treatment Studies of SORD Neuropathy with Novel Aldose Reductase Inhibitor (Rebelo et al); Yi Zhu, Amanda G. Lobato*, Adriana P. Rebelo, Tijana Canic, Sheyum Syed, Christopher Yanick, Mario Saporta, Michael Shy, Riccardo Perfetti, Shoshana Shendelman, Stephan Züchner, R. Grace Zhai, Aldose reductase inhibitor AT-007 prevents neurodegeneration and mitochondrial dysfunction in sorbitol dehydrogenase deficiency-induced neuropathy, 2022, manuscript under review; also presented at PNS 2022

yw

Sord/

AT-007 Significantly Reduced Sorbitol in Patients with SORD Deficiency in 30-Day Open-Label Pilot Trial

Pilot open-label study data in 8 SORD patients demonstrated 66% mean reduction in sorbitol (range 54%-75%)



Sorbitol Level Baseline vs. AT-007 Treatment

Safety

AT-007 safe and well tolerated; no SAEs

Pharmacokinetics/ Pharmacodynamics

- · Rapid and sustained reduction in sorbitol
- No compensatory increase in glucose level


Sorbitol Correlation with Severity

- · Baseline sorbitol correlated with disease severity
- Higher sorbitol level was associated with greater disability, need for leg braces, and upper limb involvement (tremor/ weakness)

Mean baseline sorbitol level was ~38,000ng/ml

SORD Neuropathy Phase 3 Registrational Study (INSPIRE)

Double-Blind, Randomized, Placebo-Controlled Multi-Center Study in ~50 SORD Patients >16 years old



Cross-sectional analysis of the first cohort in the INSPIRE trial confirms that sorbitol level statistically correlates with clinical outcomes

CMT-FOM Domains and Tests				
Domain	Test item			
Strength	Handgrip, ^a n Foot plantar flexion, ^a n Foot dorsiflexion, ^a n			
Upper limb function	Functional dexterity test, ^a s 9-hole peg test, ^a s			
Lower limb function	10-m walk/run, s Stair climb, s Sit to Stand, 30 s			
Balance	Stance with eyes open, ^a s Stance with eyes closed, ^a s Single leg stance, ^a s			
Mobility	Timed up and go, s 6-min walk test, ^a m			


outcome	variable	constant	p value	
10MWR	sorbitol	age	p<0.05	
4-stair-climb	sorbitol	age	p<0.05	
sit-to-stand	sorbitol	age	p<0.05	

Statistically significant correlation of sorbitol with lower limb clinical outcome measures

Confirms sorbitol as a key driver of disease severity and disease progression over time

Supports lower limb metrics evaluated in INSPIRE Phase 3 trial

Inherited Neuropathy Consortium Centers of Excellence and Global CMT Registries Exist to Support Diagnosis and Treatment



Centers participating in INSPIRE Phase 2/3 trial





PMM2-CDG Aldose Reductase Inhibition Improves PMM2 Activity AT-007 Granted Orphan & Pediatric Rare Disease Designation for PMM2-CDG; Single-Patient IND Open – Phase 2 Ready


80

PMM2-CDG[†], is an ultra-rare mutation of the PMM2 gene (phosphomannomutase) which **results in loss of PMM2 protein function and systemic deficient glycosylation of proteins, disrupting the function of critical tissues and organs**

Sorbitol is a biomarker of PMM2-CDG severity







- AR inhibition blocks the polyol pathway, restoring glucose flow through normal metabolic pathways
 - Promotes proper balance of precursor sugars necessary for protein glycosylation
 - Results in increased PMM2 activity and protein glycosylation

High unmet need with no approved therapies; ~1K cases WW, 20% infant mortality

AT-001 DIABETIC CARDIOMYOPATHY

CON

Phase 1/2 pilot study completed Registrational Phase 3 study ongoing

Diabetic Cardiomyopathy is a Form of Heart Failure Affecting ~20% of Diabetics; Significant Unmet Need with No Approved Treatments

Disease Overview

- Form of Heart Failure (Stage B) causing structural cardiac damage and resulting in decreased cardiac functional capacity
- Affects ~20% of diabetics
- Diagnosed by echocardiogram or elevated cardiac biomarkers (NTproBNP or troponin)

Standard of Care

- No approved therapies to treat DbCM or prevent progression to overt heart failure/ death
- Once DbCM patients have developed overt HF, they are eligible for standard HF therapies in addition to standard diabetes treatments

Mechanism of Disease

- Hyperactivation of the polyol pathway is a key underlying mechanism in DbCM
- Aldose Reductase activation causes intracellular sorbitol accumulation, osmotic stress, cell death, generation of ROS and impaired cardiac energetics
- Previous AR inhibitors demonstrated clinical efficacy, but were associated with off-target safety signals due to lack of selectivity

Market Size/ Opportunity

- Blockbuster potential
- Addressable population of ~6M patients US, 5M in EU5
- Anticipated pricing in line with Entresto & SGLT2s
- Composition of matter IP through 2031 (not including extensions)

DbCM: Mechanism of Disease

Normal glucose Energy Metabolism polyol pathway activation ALDOSE sorbitol glucose REDUCTASE AR activation also detracts glucose from the energy efficient Osmotic stress hexokinase/glycolytic pathway, resulting in less energy production for cardiomyocytes Oxidative damage Energy depletion AT-001 This results in heart fibrosis, a "hardening" of the heart muscle, which Cell death means it cannot effectively pump blood to the rest of the body


Both Type 1 and Type 2 diabetes results in hyperglycemia; the polyol pathway is then hyperactivated to rid the body of the excess glucose

Aldose Reductase, the first and rate limiting enzyme in the polyol pathway, converts this glucose into sorbitol and eventually fructose

Excess sorbitol and fructose cause several downstream processes that result in cell death, including osmotic dysregulation and ROS formation

Brownlee M. Diabetes Care. 2005;54(6):1615-1625; Miki T, et al. Heart Fail Rev. 2013;18(2):149-166.


Diabetic Cardiomyopathy is a Form of Stage B Heart Failure



APPLIED

THERAPEUTICS


AT-001 Has Demonstrated Effectiveness In Vitro, In Vivo, and in Phase 1/2 Clinical Trials; Registrational Study Readout Expected 2023



PRE-CLINICAL


In Vitro: AT-001 Provides Greater Potency and Improved Target Selectivity vs. "Old" Aldose Reductase Inhibitors

Applied Therapeutics' **AT-001 was developed to selectively inhibit Aldose Reductase with 1,000X greater potency and** *without* off-target inhibition of Aldehyde Reductase²




			Tissue Penetration (in rats)			
Compoun d	IC 50	MTD in animals	Systemic/ Heart	Nerve	Retina	CNS
AT-001	30pM	>2,000mg/kg	\checkmark	~	~	Х
zopolrestat	10nM	100mg/kg	~	~	Х	Х

AT-001 demonstrated improved IC₅₀ and IC₉₀ vs. zopolrestat



Data based on In Vitro Enzyme Inhibition & Cultured Hepatocytes


Unlike zopolrestrat, AT-001 does not inhibit Aldehyde Reductase




PRE-CLINICAL

AT-001 Treatment Prevents Reactive Oxygen Species Generation & Mitochondrial Stress Caused by High Glucose Exposure


Dihydroethidium (DHE) Staining for Cytosolic ROS



Quantitation of Cell Senescence Via SA-β-gal Staining




MitoSOX[™] Staining for Mitochondrial ROS




HG- NHK cells exposed to 25mM glucose (high glucose) for 48hrs HG + AT-001 - cells treated with 0.18nM AT-001 along with above mentioned HG exposure

- In patients with diabetes, metabolism of glucose through the polyol pathway results in generation of Reactive Oxygen Species (ROS), which has been identified as a key mediator of tissue damage and causal in diabetic complications. Selective inhibition of AR reduces oxidative stress and mitigates these complications.
- AT-001 prevents the production and accumulation of ROS as assessed by both DHE quantitation and MitoSOX[™] staining, demonstrating effective reduction of oxidative damage in the cytosol and mitochondria of cells.
- Evaluation via SA- β -gal staining showed less senescence in cells exposed to high glucose in the presence of AT-001


AT-001 Improves Cardiac Energetics, Prevents Cardiac Dysfunction and Prevents Fibrosis in an Animal Model of DbCM



AT-001 Improves Cardiac Function and Prevents LVH



AT-001 Prevents Fibrosis and Adverse Remodeling




APPLIED
 Keshav et al Pharmacological Inhibition of Aldose Reductase by AT-001 Prevents Abnormal Cardiac Energy Metabolism and Improves Heart Function in an Animal Model of Diabetic Cardiomyopathy, AHA 2020;
 Keshav et Al Aldose Reductase Inhibition By At-001 Alleviates Fibrosis and Adverse Remodeling In Diabetic Cardiomyopathy By Reducing Myocardial Fatty Acid Oxidation, AHA 2022

PHASE 1/2


Phase 1: AT-001 Normalizes Sorbitol, a Biomarker of AR Activity, in Diabetic Patients

Proof of Biological Activity




AT-001 normalized sorbitol in diabetics to healthy volunteer levels


No compensatory increase in glucose level



Mean reduction in sorbitol at Day 1 and Day 7: Results are persistent over 1 week of treatment

At 40mg/kg patients were normalized to healthy volunteer sorbitol levels, demonstrating complete AR inhibition





Rapid release capsule provides sorbitol normalization effects (PD biomarker) through **10-12hrs post-dose** at >10mg/kg


Includes protection from food-related sorbitol spikes during times of post-prandial hyperglycemia

APPLIED Poster, "Phase 1/2 Safety and Proof of Biological Activity Study of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy" American Diabetes Association 79th Scientific Sessions in San Francisco (June 7-11, 2019); Poster "Clinical Assessment of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy: a 28 day proof of concept study" American Heart Association (AHA) Scientific Sessions

PHASE 1/2

Phase 2: AT-001 Reduced Levels of NTproBNP Cardiac Stress Biomarker Over 28 Days


Sorbitol Normalization



Significant sorbitol reduction achieved by both 1,000mg TID and 1,500mg BID AT-001


Higher Cmax achieved with BID slightly beneficial — normalizes sorbitol to healthy volunteer levels

Mean Reduction in NTproBNP



Mean reduction in NTproBNP seen over 28 days vs. placebo

Mean baseline NTproBNP was 65pg/ml




~50% AT-001 treated patients demonstrated a clinically meaningful reduction in NTproBNP over 28 days

>25pg/ml reduction from baseline

DbCM Phase 3 Registrational Study (ARISE-HF)

Randomized, Placebo-Controlled Study in DbCM Patients at High Risk of Progression



Key Projected Milestones by Program

